WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
maximize
Machine translation
1. (WO2012099886) COMPOSITIONS AND MEHTHODS FOR MODULATING GAMMA-C-CYTOKINE ACTIVITY
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

WHAT IS CLAIMED IS:

1. An isolated or purified peptide, comprising amino acid sequence D/E-F-L-E/Q/N-S/R-X-I/K-X-L/I-X-Q (SEQ ID NO: 2), wherein X denotes any amino acid and wherein the peptide can inhibit the activity of one or more ye-cytokines selected from the group consisting of: IL-2, IL-4, IL-7, IL-9, IL-15 or IL-21.

2. The isolated or purified peptide according to claim 1, wherein the peptide comprises the amino acid sequence I-K-E-F-L-Q-R-F-I-H-I-V-Q-S-I-I-N-T-S (SEQ ID NO: 1) (ΒΝΖ-γ).

3. The isolated or purified peptide according to claim 1, wherein the peptide consists essentially of amino acid sequence I-K-E-F-L-Q-R-F-I-H-I-V-Q-S-I-I-N-T-S (SEQ ID NO: 1) (ΒΝΖ-γ).

4. The isolated or purified peptide according to any one of claims 1 to 3, wherein the peptide inhibits the activity of IL-15 and IL-19.

5. An isolated or purified peptide comprising, a peptide derivative of the amino acid sequence I-K-E-F-L-Q-R-F-I-H-I-V-Q-S-I-I-N-T-S (SEQ ID NO: 1), wherein the amino acid sequence of the derivative peptide has similar physico-chemical properties as a peptide of the amino acid sequence I-K-E-F-L-Q-R-F-I-H-I-V-Q-S-I-I-N-T-S (SEQ ID NO: 1), but has distinct biological activity, wherein the biological activity is inhibition of the activity of IL-15 and IL-9.

6. The peptide of claim 5, where in the amino acid sequence of the derivative shares at least about 50% identity with a peptide of amino acid sequence I-K-E-F-L-Q-R-F-I-H-I-V-Q-S-I-I-N-T-S (SEQ ID NO: 1).

7. A method for blocking signaling by one or more yc-cytokine family members, comprising contacting a cell with the isolated or purified peptide of any one of claims 1 to 6.

8. A method of inhibiting yc-cytokine binding to a yc-subunit comprising contacting a yc-subunit with the isolated or purified peptide of any one of claims 1 to 6.

9. A pharmaceutical composition comprising a therapeutically effective amount of a isolated or purified peptide of any one of Claims 1 to 6, or a derivative thereof, and a pharmaceutically acceptable carrier, diluent, excipient or combination thereof.

10. Use of a isolated or purified peptide of any one of Claims 1 to 6, or a derivative thereof, or a pharmaceutical composition of Claim 9 for preparing a medicament for ameliorating or treating a yc-cytokine-mediated disease.

11. The use of claim 10, wherein the yc-cytokine-mediated disease is selected from the group consisting of: CD4-leukemia, CD8-leukemia, LGL-leukemia, systemic lupus erythematosis, Sjoegren's syndrome, Wegener's granulomatosis, Celiac disease, Hashimoto's thyroiditis, rheumatoid arthritis, inflammatory bowel disease, diabetes mellitus, psoriasis, multiple sclerosis, uvietis, inflammation of the eye, and graft-versus-host disease (GvHD).

12. Use of a isolated or purified peptide of any one of Claims 1 to 6, or a derivative thereof, or a pharmaceutical composition of Claim 9 for preparing a medicament for ameliorating or treating a HTLV-1 -associated myelopathy (HAM)/ tropical spastic paraparesis (TSP) associated disease.

13. The use of claim 12, wherein the HAM/TSP associated disease is selected from the group consisting of: Adult T-cell Leukemia (ATL), HTLV-associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP), and other non-neeoplastic inflammatory diseases associated with HTLV such as uveitis (HU), arthropathy, pneumopathy, dermatitis, exocrinopathy and myositis.

14. Use of a isolated or purified peptide of any one of Claims 1 to 6, or a derivative thereof, or a pharmaceutical composition of Claim 9 for preparing a medicament for ameliorating or treating a inflammatory respiratory disease.

15. The use of claim 12, wherein the inflammatory respiratory disease is selected from the group consisting of: asthma, sinusitis, hay fever, bronchitis, chronic obstructive pulmonary disease (COPD), allergic rhinitis, acute and chronic otitis, and lung fibrosis.

16. A method of using a peptide of any one of Claims 1 to 6, or a derivative thereof, or a pharmaceutical composition of Claim 9 for a cosmetic purpose, wherein the cosmetic purpose is selected from the group consisting of: treatment of acne, treatment of hair loss, treatment of sunburn, nail maintenance, and reduction in the appearance of aging.